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Lis
Yo
MaBACKGROUND Critical impairment of adaptive immune response has been observed in patients with acute coronary
syndromes (ACS) with reduced expansion of regulatory T cells (Treg) and enhanced effector T-cell responsiveness, both
associated with poorer outcomes.
OBJECTIVES This study investigated the mechanisms underlying T-cell dysregulation in ACS.
METHODS We evaluated both early and downstream T-cell receptor activation pathways after ex vivo stimulation with
anti-CD3 and anti-CD28 crosslink in CD4þ T cells from 20 patients with non-ST-segment elevation myocardial infarction
(NSTEMI), 20 with stable angina (SA), and 20 controls. We reassessed 10 NSTEMI and 10 SA patients after 1 year.
RESULTS Phospho-ﬂow analysis revealed reduced phosphorylation of the zeta-chain–associated protein kinase of
70 kDa at the inhibitory residue tyrosine 292, enhancing T-cell activation, in NSTEMI helper T cells versus SA and controls
(each, p < 0.001), resulting from increased expression of the protein tyrosine phosphatase, nonreceptor type, 22
(PTPN22) (p < 0.001 for both comparisons), persisting at follow-up. We also observed reduced phosphorylation
(p < 0.001 versus controls) and lower levels of binding to interleukins 2 and 10 core promoter regions of the tran-
scription factor cyclic adenosine monophosphate response element-binding protein (CREB) in NSTEMI (p < 0.05 vs.
controls), which recovered at 1 year. Finally, in NSTEMI patients, helper T cells had a reduced ability in T-cell receptor–
induced Treg generation (p ¼ 0.002 vs. SA; p ¼ 0.001 vs. controls), partially recovered at 1 year. Restoring CREB activity
and silencing PTPN22 enhanced NSTEMI patients’ ability to generate Treg.
CONCLUSIONS The persistent overexpression of PTPN22 and the transient reduction of CREB activity, associated with
impaired Treg differentiation, might play a role in ACS. (J Am Coll Cardiol 2015;65:1175–86) © 2015 by the American
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ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome(s)
CREB = cyclic adenosine
monophosphate response
element–binding protein
IL = interleukin
mRNA = messenger
ribonucleic acid
NSTEMI = non-ST-segment
elevation myocardial infarction
OA = okadaic acid
PTPN22 = protein tyrosine
phosphatase, nonreceptor
type, 22
SA = stable angina
TCR = T-cell receptor
Treg = regulatory T cell
ZAP-70 = zeta-chain–associated
protein kinase of 70 kDa
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1176regression of atherosclerosis and stabiliza-
tion of plaque (3).
The transition from coronary stability to
instability, however, is less well understood
as we lack animal models. The abrupt clinical
presentation of ACS gives a strong signal of
discontinuity in the natural history of athero-
thrombosis. The causes of such discontinuity
are complex, probably multiple, and still
largely unknown (4).SEE PAGE 1187In ACS, helper T-cell (CD4þ lymphocyte)
subpopulations are dysregulated, and their
abnormalities are associated with poorer
outcomes (5–11). In particular, ACS patients
have a reduced expansion of Treg (8,11–13),
and lymphocytes in ACS patients show
T-cell receptor (TCR) signaling abnormalities
leading to enhanced effector T-cell re-
sponsiveness (14,15). The putative molecu-lar mechanisms involved in these TCR signaling
abnormalities are also unclear.
Beyond the cytokine environment, TCR signal
strength is important in generating different T-cell
subsets (16–18). In particular, strong upstream TCR-
signaling activation seems to negatively modulate
Treg differentiation (18).
Protein phosphatases, signal-transducing enzymes
that dephosphorylate cellular phosphoproteins, play a
key role in controlling the intensity of TCR activation.
Protein tyrosine phosphatase, nonreceptor type, 22
(PTPN22) controls early TCR-signal transduction
acting on lymphocyte-speciﬁc protein tyrosine kinase
and on zeta-chain–associated protein kinase of 70 kDa
(ZAP-70) (19,20). A recent study showed a crucial role
of PTPN22 in the regulation of murine Treg function,
expression, and survival (21).
TCR triggering initiates a complex network of
signaling events that activate several downstream
pathways, including cyclic adenosine mono-
phosphate response element–binding protein (CREB)
(22), a molecule that plays different roles in immune
function, particularly Treg generation and mainte-
nance, and the production of interleukin (IL)-2 (23), a
key cytokine essential for Treg function (24). In
experimental models of cardiovascular disease, CREB
is down-regulated by risk factors (25).
In this study, we compared early TCR-activation
pathways in patients with non-ST-segment elevation
myocardial infarction (NSTEMI) to those in patients
with stable angina (SA) and in controls. We studied the
role of PTPN22 in modulating ZAP-70 activation and
Treg differentiation, plus we assessed downstreamTCR-activation pathways, in particular CREB activity.
We reanalyzed NSTEMI and SA patients at 1-year
follow-up, during a stable phase of coronary artery
disease. Additionally, to dissect the role of a general
inﬂammatory response (e.g., that characterizing
NSTEMI patients) in TCR abnormalities, we per-
formed additional experiments in healthy controls
in the presence of the proinﬂammatory cytokine IL-6.
METHODS
We enrolled 20 patients admitted to our coronary care
unit with a diagnosis of NSTEMI, deﬁned as a rise and
fall of cardiac troponin T and at least one of the
following: angina, ST-segment depression, and
T-wave inversion. We also enrolled 20 patients with
chronic SA admitted to our cardiovascular ward to
undergo coronary angiography because of severe
symptoms and/or high-risk abnormalities on nonin-
vasive testing, and 20 patients >50 years of age at
intermediate risk for cardiovascular disease and
without a history of and/or current symptoms or signs
of ischemic heart disease (controls).
We drew venous blood samples at patient enroll-
ment. In ACS, we collected venous blood samples
within 24 h of symptom onset (mean: 11.5  5.7 h).
We obtained peripheral blood mononuclear cells
from whole blood samples by standard-gradient
centrifugation over Ficoll-Hypaque (GE Healthcare
Bio-Sciences, Piscataway, New Jersey).
STATISTICAL ANALYSIS. The continuous variables
that were normally distributed, as assessed by the
Shapiro-Wilk test, were described as mean  SEM and
analyzed with parametric tests. For comparisons
among the 3 groups,we used 1-way analysis of variance
(ANOVA) with Bonferroni correction. For multiple
pairwise comparisons, we used 2-way ANOVA for
repeated measures, with Bonferroni correction. For
between-group comparisons, we used an unpaired
Student t test. To compare the means of 2 related
samples within groups, we used a paired-samples
Student t test. For correlations, we used the Pearson’s
test. Values of high-sensitivity C-reactive protein
that were non-normally distributed were described
as median (range) and compared using the Kruskal-
Wallis nonparametric ANOVA, with the Dunn’s test
for comparisons among groups. Proportions were
compared using the chi-square test. A 2-tailed p value
<0.05 was considered statistically signiﬁcant. Statis-
tical analysis was performed with GraphPad Prism
version 5.00 (GraphPad Software, San Diego, Califor-
nia) and SPSS version 18.0 (SPSS Inc., Chicago, Illinois).
For a detailed description of all methods, see the
Online Appendix.
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1177RESULTS
Characteristics of the study population are reported
in Online Table 1. All biological parameters are pre-
sented in Online Tables 2 and 3.
We performed TCR-signaling experiments in all
study patients. After stimulation with anti-CD3 and
anti-CD28 crosslink, phosphorylation of ZAP-70 at
regulatory residue tyrosine 292 (Y-292) in helper T cells
was reduced in the NSTEMI group compared with thatFIGURE 1 Altered Early TCR Signaling in Helper T Cells in NSTEMI
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ylation at ZAP-70Y-319 (Figure 1B). InNSTEMI patients,
early tyrosine phosphorylation events were enhanced
comparedwith those in SA patients and controls (both,
p < 0.001) (Figure 1C), conﬁrming the TCR hyper-
reactivity previously described in ACS (15).
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1178higher expression of both PTPN22 messenger ribo-
nucleic acid (mRNA) (p ¼ 0.001 vs. SA; p < 0.001 vs.
controls) and PTPN22 protein (both, p < 0.001)
(Figure 1D). In the overall study population, PTPN22
expression was positively correlated with phospho-
tyrosine levels (r = 0.377; p ¼ 0.003) and nega-
tively with ZAP-70 Y-292 phosphorylation (r = –0.476;
p ¼ 0.001) (Figure 1E). Online Table 4 shows the pre-
dictors of PTPN22 at multivariate logistic regression
analysis.
To investigate TCR activation during a stable phase
of the disease, we reassessed 10 NSTEMI patients and
10 SA patients after 1-year follow-up. None of the
patients had experienced an event during the follow-
up period. As observed at the time of the index event,
ZAP-70 Y-292 phosphorylation was reduced in theEarly TCR Signaling in NSTEMI Versus SA Patients at 1 Year
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tients (both, p < 0.001) (Figure 2B, Online Figure 1).
Moreover, at 5 min after TCR stimulation, we
observed an enhancement of early tyrosine phos-
phorylation events in the helper T cells of NSTEMI
patients compared with those in SA patients
(p < 0.001) (Figure 2C), conﬁrming that TCR hyper-
reactivity persisted after the acute phase of ACS.
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1179(r = –0.602; p < 0.005) (Figure 2D). Changes over
time in each group are shown in Online Figure 1.
To investigate downstream TCR-signaling pathway
activation, we assessed the phosphorylation of the
well-characterized transcription factor CREB in the
same 20 patients in each group.
NSTEMI patients exhibited a lower phosphoryla-
tion of CREB at residue serine 133 at 2 and 5 min after
TCR stimulation compared with that in controls
(p < 0.001) (Figure 3A). We also analyzed the biolog-
ical activity of CREB by assessing its intranuclear
localization and its binding levels to the IL-2, IL-10,
Foxp3, and c-fos promoter regions in ﬁve patients in
each group. CD4þ T cells from NSTEMI patients
exhibited reduced intranuclear localization of CREB
after TCR stimulation (p ¼ 0.045 vs. controls)
(Figure 3B) and reduced binding levels of CREB to IL-2
and IL-10 core promoter regions compared with con-
trols (IL-2: p ¼ 0.024; IL-10: p ¼ 0.001); we did not
ﬁnd statistical differences in CREB binding to Foxp3
and c-fos promoters (Figure 3C).
CREB is required for generating and maintaining
Tregs (23); therefore, we evaluated TCR-induced Treg
generation. After 6 days of TCR stimulation, differ-
entiation of Treg (identiﬁed as CD4þCD25þCD127low
Foxp3þ) was reduced in NSTEMI patients compared
with that in SA patients and controls (p < 0.001)
(Figure 3D).
At 1-year follow-up, stimulated helper T-cell CREB
phosphorylation was signiﬁcantly increased from
baseline in the NSTEMI and SA groups (p < 0.01 for all
comparisons) (Figure 3E, Online Figure 1). Moreover,
in NSTEMI patients, the proportion TCR-induced
Tregs in the helper T cells was greater at follow-up
compared with that observed at the time of the
index event (p < 0.05), although less than those
observed at follow-up in SA patients and in controls
(p ¼ 0.03 and p ¼ 0.01, respectively) (Figure 3F, Online
Figure 1). Changes over time in each group are shown
in Online Figure 1.
To conﬁrm whether restoring CREB activity re-
sults in increased Treg induction in ACS, we treated
helper T cells from NSTEMI patients with okadaic
acid (OA) (2 nM), an inhibitor of the catalytic sub-
unit of protein phosphatase 2A involved in CREB
dephosphorylation. With OA treatment, CREB phos-
phorylation in the TCR-stimulated helper T cells was
increased in NSTEMI patients (n ¼ 5) (Figure 4A).
Moreover, with OA treatment, Foxp3, IL-10, and IL-2
mRNA expression were increased (although not
signiﬁcantly so for IL-2), but transforming growth
factor-b mRNA expression was not (Figure 4B).
Finally, we evaluated the TCR-induced Treg gener-
ation in ACS, SA, and controls with or withoutOA (n ¼ 10 per group). After 6 days of TCR stimu-
lation, OA treatment was associated with signiﬁ-
cantly increased Treg frequency in the three groups
(Figure 4C).
To determine the role of PTPN22 in TCR signaling
and in Treg differentiation in ACS, we transfected the
cells of 5 NSTEMI patients with PTPN22-targeting
small interfering RNA (siRNA). After 48 h of trans-
fection, we observed reduced PTPN22 expression
(Figure 5A) and increased ZAP-70 Y-292 phosphory-
lation (Figure 5B). We analyzed the expression of Treg
after 48 h of TCR stimulation. Helper T cells in
NSTEMI patients transfected with PTPN22-targeting
siRNA showed an increased frequency of Treg (iden-
tiﬁed as CD4þCD25þCD127lowFoxp3þ) (p ¼ 0.001)
(Figure 5C).
To evaluate the role of an inﬂammatory environ-
ment in the observed TCR pathway abnormalities,
we stimulated peripheral blood mononuclear cells
from 5 controls with aCD3/aCD28 in the presence
of IL-6. As shown in Figure 6A, IL-6 treatment was
associated with increased CREB and ZAP-70 Y-292
phosphorylation after 24 and 72 h of TCR stimulation,
but no difference was observed in ZAP-70 Y-319
activation. Furthermore, after 24 h of stimulation,
down-regulation of PTPN22 expression was induced
with both IL-6 alone and TCR stimulation alone
(Figure 6B), whereas TCR activation with aCD3/aCD28
in the presence of IL-6 did not affect PTPN22
expression. No differences in Treg generation after
IL-6 treatment were observed (Figure 6C).
DISCUSSION
In our study, a double-impairment of TCR signaling in
NSTEMI patients resulted in enhanced effector T-cell
responsiveness and reduced Treg generation. These
TCR-signaling abnormalities consist of a persistent
increased expression of the protein tyrosine phos-
phatase PTPN22 that modulates early TCR activation,
and a transient reduced activity, during the acute
phase of the disease, of the transcription factor CREB
(Central Illustration).
Several studies have highlighted the role of PTPN22
in T-cell activation and autoimmunity, particularly
the association of the PTPN22 R620W allelic variant
with autoimmune disease development (20). Know-
ledge of PTPN22 derives mainly from studies of its
mouse orthologue, hence the precise mechanism of
how PTPN22 regulates the immune cell function in
humans is not entirely deﬁned and remains con-
troversial. Nonetheless, this phosphatase plays an
important role in immune homeostasis, regulating
both effector and regulatory T-cell function in vivo.
FIGURE 3 Transient Reduction of CREB Activity in Helper T Cells
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FIGURE 4 Restored CREB Activity Increases Treg Induction in ACS
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Values are mean  SEM. TGF ¼ transforming growth factor; other abbreviations as in Figures 1 and 3.
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1181A substrate of PTPN22 is ZAP-70, a protein kinase
key in the early steps of T-cell activation involved in
the ﬁne regulation of TCR-signal transduction (26).
Among several tyrosine residues of ZAP-70, Y-292 is
involved in down-modulation of the TCR/CD3 com-
plex during the immunological synapse formation and
of the proximal events in TCR signaling (26–28). The
reduced ZAP-70 Y-292 activation that we observed in
NSTEMI patients is consistent with the increased
TCR/CD3 recruitment in T cells in ACS and with the
enhanced early TCR-induced phosphorylation events
demonstrated here and in previous studies (14,15).
PTPN22 acts on several substrates, including the
activating Y-394 on lymphocyte-speciﬁc protein
tyrosine kinase and Y-493 on ZAP-70 (19). Thephosphorylation of these residues enhances T-cell
activation; accordingly, the increased PTPN22 ex-
pression in NSTEMI patients that dephosphorylates
these residues should be expected to reduce, not
enhance, T-cell activation. We propose that in
NSTEMI patients, the higher expression of PTPN22,
increasing ZAP-70 Y-292 dephosphorylation, reduces
the negative-feedback loop controlled by this inhibi-
tory residue, thus enhancing TCR signaling. This
working hypothesis also might explain why the poly-
morphic gain-of-function variant of PTPN22, R620W,
is associated with several autoimmune diseases.
The importance of the TCR signal strength in
differentiating helper T-cell subsets has increasingly
been deﬁned; in particular, strong TCR signaling in
FIGURE 5 PTPN22 Silencing Enhances ZAP-70 Y-292 Signaling and Treg Induction
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1182early activation stages negatively regulates Treg dif-
ferentiation (16–18). ACS patients have low levels
of circulating Treg (8,11–13), and here we have
demonstrated a reduced ability of helper T cells in
TCR-induced Treg generation in NSTEMI patients.
Hence, the persistent higher expression of PTPN22 in
NSTEMI patients, altering the threshold of TCR
signaling, might well play a role also in reduced Treg
expansion. Of note, a lack of PTPN22 increases both
the induction and the immunosuppressive function
of extrathymic murine Treg (21). Our experiments in
CD4þ T cells from NSTEMI patients transfected with
PTPN22-targeting siRNA seem to conﬁrm the role of
PTPN22 in ZAP-70 Y-292 dephosphorylation and Treg
induction. Moreover, our ﬁndings in healthy controls,after in vitro stimulation with the proinﬂammatory
cytokine IL-6, suggest that the effects observed in
NSTEMI patients are not secondary to the inﬂamma-
tory status in these patients and are rather primary
and/or “intrinsic” T-cell abnormalities. In particular,
IL-6 stimulation was associated with reduced PTPN22
expression and increased ZAP-70 phosphorylation at
its inhibitory residue, Y-292.
PTPN22-enhanced expression and the associated
early TCR signaling abnormalities in NSTEMI patients
were still present at 1-year follow-up, yet the ability
of helper T cells from NSTEMI patients to generate
Treg was partially recovered at 1 year after the index
event. This partial recovery might have been related
to a transient defective phosphorylation of CREB, a
FIGURE 6 IL-6 Modulates CREB, ZAP-70 Phosphorylation, and PTPN22 Expression in CD4þ T Cells
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1183transcription factor that plays a key role in Treg
generation (23). Indeed, this defective phosphoryla-
tion, conﬁned to the acute phase of ACS, substantially
improves at 1-year follow-up. Phosphorylation of
CREB results in an increased expression of the anti-
inﬂammatory cytokine IL-10 and Treg generation, as
observed in our study.Phospho(p)-ZAP-70 Y-292 (pY292) is a crucial res-
idue that negatively regulates TCR activation. The
reduced pY292 (probably due to increased expression
of PTPN22) in NSTEMI should be expected to
enhance, not reduce, CREB phosphorylation. Indeed,
during the acute settings of NSTEMI, we observed
strong upstream TCR activation and paradoxically
CENTRAL ILLUSTRATION TCR Signaling and NSTEMI-ACS
In this schematic outline of T-cell receptor (TCR) signaling in acute coronary syndromes (ACS), impairment of the adaptive immune response in
patients with non-ST-elevation myocardial infarction (NSTEMI) may stem from the inﬂuence of 2 distinct paths. In 1, persistent increased
expression of the protein tyrosine phosphatase nonreceptor type 22 (PTPN22) leads to reduced phosphorylation of the zeta-chain–associated
protein kinase of 70 kDa at the inhibitory residue tyrosine 292 (ZAP-70 Y-292). In the other, transient reduced activity of the transcription
factor cyclic adenosine monophosphate response element–binding protein (CREB) reduces regulatory T-cell (Treg) differentiation. When
paired, the 2 pathways lead to increased T-cell activation, all of which may play a role in ACS.
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1184weak downstream CREB activation. Thus, the
increased CREB activation in NSTEMI at 1-year
follow-up, associated with the persistent reduction of
pY292 and increased expression of PTPN22, seems
reasonable. A possible explanation might come from
the recent observation that the expression of the
immunomodulatory molecule CD31 is transiently
reduced in helper T cells in ACS patients, limited to
the acute phase of the disease (14). This molecule in-
terferes with the mitogen-activated protein kinases
involved in CREB pathways. Thus, the reduced
expression of CD31 in acute-phase ACS might con-
tribute to the reduced CREB activation. However,
CREB phosphorylation is regulated by several stimuli
beyond TCR triggering (29); recent evidence in exper-
imental models of cardiovascular disease suggests
that CREB phosphorylation is down-regulated by risk
factors (25). Therefore, a prolonged exposure to envi-
ronmental stressors, such as oxidized low-density
lipoprotein, might lead to altered CREB pathways.
Finally, the reduced levels of binding to IL-2 and
IL-10, but not to the Foxp3 promoter regions,observed in the NSTEMI patients underline the
complexity of genetic and epigenetic mechanisms
involved in Treg differentiation. Indeed, Foxp3 is
under the control of transcription factors other than
CREB. In particular, the Janus kinase/signal trans-
ducers and activators of transcription pathway, trig-
gered by both IL-2 and IL-10, is a principal player in
Foxp3 induction and in Treg function and generation
(24,30). Thus, the reduced CREB activation might
inﬂuence Treg induction by reducing the production
of these cytokines.
STUDY LIMITATIONS. Our study was a prospective
observational analysis that included a limited number
of patients. No power calculation could be performed
because of a lack of previous studies in this setting;
thus, the enrollment of 20 patients in each group was
arbitrary. NSTEMI and SA patients and controls were
not properly matched for age, sex, and risk factors;
however, no signiﬁcant differences were observed in
these regards between the NSTEMI and SA groups,
and none of these variables were independently
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Elevated soluble
markers of inﬂammation in patients with ACS are associated with
worse outcomes, and T-cell dysregulation is pivotal to the
immune response.
TRANSLATIONAL OUTLOOK: Markers of adaptive immunity,
such as PTPN22 and CREB, may be more accurate guides to
prognosis in patients with ACS and could be useful in developing
speciﬁc anti-inﬂammatory treatments.
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1185associated with PTPN22 expression and ZAP-70 Y-292
and CREB phosphorylation on univariate analysis.
These limitations imply two dominant methodological
issues that cannot be eluded. First, several variables
other than the coronary disease state might explain
the differences observed across these three pop-
ulations. Second, it is impossible in this type of study
to determine a cause–effect relationship. Although we
performed in vitro experiments using IL-6 stimulation
to simulate a proinﬂammatory environment and
exclude potential upstream determinants, we cannot
rule out that the reduced CREB activity might have
been a part of the general stress response in acute
phase ACS. Moreover, in our experimental conditions
(cell transfection with targeting siRNA), PTPN22
silencing induced only a modest, although signiﬁcant,
increase in Treg frequency, so further studies are
needed. Finally, we focused our attention on TCR-
mediated signal transduction pathways only, ex-
cluding the role of cytokine signaling. A shift in the
TCR threshold setting does not eliminate the role of
the cytokine environment as a key factor in controlling
T-cell activity and differentiation. Further and deeper
studies will help to determine the role of cytokine
signaling, in particular IL-2 and IL-10, in ACS. How-
ever, a strong upstream TCR activation associated
with weak downstream CREB activation may set
the stage for an enhanced immune responsiveness
unhampered by immune tolerance.CONCLUSIONS
Our study adds novel pieces of information to the
important role of adaptive immunity alterations in
ACS. PTPN22 and CREB might represent novel po-
tential therapeutic targets as well as biomarkers in
the subset of ACS patients in whom an inﬂammatory
outburst is the likely cause of coronary instability.
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